Pyxis Oncology Secures Up to $114M Financing, Extends Cash Runway to Q2 2027
PYXS has more than doubled off its 52-week low of $0.97 on elevated volume (2.0× avg).
Summary
Pyxis Oncology announced a private placement financing expected to bring in $50 million upfront and up to an additional $64 million from warrant exercises, totaling up to $114 million. This critical funding extends the company's cash runway into the second quarter of 2027, directly addressing the 'going concern' warning and critically short cash runway reported in the May 14th 10-Q. The financing significantly de-risks the company's financial position and allows it to continue advancing its lead MICVO program through key clinical milestones. Investors should watch for updated Phase 1 monotherapy data in Fall 2026 and Phase 1/2 combination data in Q4 2026.
At the time of this announcement, PYXS was trading at $3.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $181.2M. The 52-week trading range was $0.97 to $5.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.